Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751815 | 0.78 | MGLL (0.61) | MGLLMEN1KMT2APGRL3MBTL1 | |
| SCHEMBL29644716 | 0.77 | MGLL (0.55) | MGLLMEN1KMT2APGRL3MBTL1 | |
| SCHEMBL15437831 | 0.77 | MGLL (0.55) | MGLLMEN1KMT2APGRL3MBTL1 | |
| SCHEMBL16089511 | 0.77 | MGLL (0.55) | MGLLMEN1KMT2AL3MBTL1NR1H2 | |
| SCHEMBL15438011 | 0.77 | MAPT (0.43) | MEN1KMT2AL3MBTL1NR1H2ALDH1A1 | |
| SCHEMBL8460073 | 0.76 | L3MBTL1 (0.60) | MGLLMEN1KMT2APGRL3MBTL1 | |
| SCHEMBL1473515 | 0.75 | MGLL (0.53) | MGLLMEN1KMT2APTGS1PTGS2 | |
| SCHEMBL23312265 | 0.74 | MGLL (0.57) | MGLLMEN1KMT2APGRL3MBTL1 | |
| SCHEMBL15197568 | 0.74 | MGLL (0.57) | MGLLMEN1KMT2APGRL3MBTL1 | |
| SCHEMBL15437728 | 0.73 | RAD51 (0.49) | MGLLMEN1KMT2APTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | claimed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | claimed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | claimed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296690-B2 | Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2016-03-29 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | METACINE, INC. (KR) | 2014-09-18 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | METACINE, INC. (KR) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031563-A1 | New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof | SOST, MYD88, MSR1 | MGLL 4191/4885MEN1 325/4885KMT2A 2720/4885 |
| US-20140275203-A1 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof | SOST, MYD88, MSR1 | MGLL 4069/4885MEN1 508/4885KMT2A 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.